Pluristem Therapeutics Inc. (NASDAQ:PSTI) Major Shareholder Purchases $411,962.64 in Stock

Pluristem Therapeutics Inc. (NASDAQ:PSTI) major shareholder Clover Wolf Capital – Limited acquired 49,396 shares of the business’s stock in a transaction on Monday, July 27th. The shares were purchased at an average cost of $8.34 per share, for a total transaction of $411,962.64. Following the completion of the transaction, the insider now owns 3,460,842 shares in the company, valued at approximately $28,863,422.28. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Clover Wolf Capital – Limited also recently made the following trade(s):

  • On Wednesday, July 29th, Clover Wolf Capital – Limited bought 121,926 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $9.03 per share, with a total value of $1,100,991.78.
  • On Monday, June 29th, Clover Wolf Capital – Limited bought 110,897 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $8.41 per share, with a total value of $932,643.77.
  • On Wednesday, June 24th, Clover Wolf Capital – Limited bought 25,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $8.05 per share, with a total value of $201,250.00.
  • On Monday, June 22nd, Clover Wolf Capital – Limited bought 59,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.36 per share, with a total value of $434,240.00.
  • On Thursday, June 18th, Clover Wolf Capital – Limited bought 49,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.36 per share, with a total value of $360,640.00.
  • On Wednesday, June 10th, Clover Wolf Capital – Limited bought 25,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $6.91 per share, with a total value of $172,750.00.
  • On Monday, June 8th, Clover Wolf Capital – Limited bought 178,717 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.36 per share, with a total value of $1,315,357.12.
  • On Thursday, June 4th, Clover Wolf Capital – Limited acquired 7,610 shares of Pluristem Therapeutics stock. The stock was purchased at an average price of $7.86 per share, with a total value of $59,814.60.
  • On Tuesday, June 2nd, Clover Wolf Capital – Limited acquired 117,489 shares of Pluristem Therapeutics stock. The stock was purchased at an average price of $7.57 per share, with a total value of $889,391.73.
  • On Sunday, May 31st, Clover Wolf Capital – Limited acquired 1,797 shares of Pluristem Therapeutics stock. The stock was purchased at an average price of $7.95 per share, with a total value of $14,286.15.

Shares of PSTI stock opened at $9.15 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.47 and a current ratio of 2.47. The company’s 50-day simple moving average is $8.43 and its two-hundred day simple moving average is $6.49. Pluristem Therapeutics Inc. has a one year low of $2.82 and a one year high of $13.29.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Evolution Wealth Advisors LLC purchased a new position in shares of Pluristem Therapeutics during the second quarter worth $27,000. Focused Wealth Management Inc acquired a new stake in shares of Pluristem Therapeutics in the second quarter valued at about $53,000. Levin Capital Strategies L.P. acquired a new stake in shares of Pluristem Therapeutics in the first quarter valued at about $37,000. ETF Managers Group LLC boosted its position in Pluristem Therapeutics by 9.8% during the first quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 5,764 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in Pluristem Therapeutics by 303.9% during the fourth quarter. Jane Street Group LLC now owns 67,349 shares of the biotechnology company’s stock worth $265,000 after acquiring an additional 50,674 shares during the last quarter. 7.82% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 30th. Maxim Group restated a “buy” rating and issued a $12.00 price objective on shares of Pluristem Therapeutics in a report on Friday, May 15th. Jefferies Financial Group boosted their target price on shares of Pluristem Therapeutics from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, July 24th. ValuEngine lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Finally, Dawson James reiterated a “buy” rating on shares of Pluristem Therapeutics in a research note on Wednesday, April 15th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Pluristem Therapeutics has a consensus rating of “Buy” and a consensus price target of $13.00.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

See Also: What is the price-sales ratio?

Insider Buying and Selling by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.